Validity of ICD 10 Codes for Cerebral Venous Thrombosis Depends on Clinical Context

Background: Recent reported population-based rates of cerebral venous thrombosis (CVT) are higher than in older studies, though the context of these diagnoses is not well-defined. To better understand these trends, we examined the accuracy of administrative codes ( ICD-10 ) for CVT in different clinical scenarios. Methods: Cases of CVT presenting to a tertiary center between 2008-2018 were identified in two ways: free text search through all hospital electronic radiology reports regardless of modality and body part and any ICD-10 discharge codes (see Table 1). Electronic medical records were reviewed to verify diagnoses of CVT and their clinical context (Figure 1) to calculated Positive Predictive Value (PPV) of ICD-10 codes. Additionally, sensitivities of ICD-10 codes were calculated against all CVTs identified using either searches that were verified on chart review as the gold standard. Results: There were 289 confirmed cases: 239 new diagnoses, 204 of which were acute events. Only 75 cases (37%) were new, symptomatic CVTs not provoked by trauma or structural processes. Sensitivity and PPV for ICD-10 codes depending on clinical context is reported in Table 1. Conclusion: The majority of CVT identified at our institution were incidentally diagnosed in context of intracranial processes such as trauma, surgery, infection, or masses; 37% were symptomatic, non-structural incident diagnoses. Our findings have implications in interpreting CVT rates identified through administrative data, as the management and prognosis of CVT may differ based on clinical context.

Download Full-text

Validation of ICD-10 codes shows intracranial venous thrombosis incidence to be higher than previously reported

Health Information Management Journal ◽

10.1177/1833358318819105 ◽

2018 ◽

Vol 49 (1) ◽

pp. 58-61 ◽

Cited By ~ 2

Author(s):

Joel D Handley ◽

Hedley CA Emsley

Keyword(s):

Positive Predictive Value ◽

Cerebral Infarction ◽

Venous Thrombosis ◽

Cerebral Venous Thrombosis ◽

International Classification Of Diseases ◽

Coding System ◽

Classification Of Diseases ◽

Icd 10 ◽

In Pregnancy

Background: Intracranial venous thrombosis (ICVT) accounts for around 0.5% of all stroke cases. There have been no previously published studies of the International Classification of Diseases, Tenth Edition (ICD-10) validation for the identification of ICVT admissions in adults. Objective: The aims of this study were to validate and quantify the performance of the ICD-10 coding system for identifying cases of ICVT in adults and to derive an estimate of incidence. Method: Administrative data were collected for all patients admitted to a regional neurosciences centre over a 5-year period. We searched for the following ICD-10 codes at any position: G08.X (intracranial and intraspinal phlebitis and thrombophlebitis), I67.6 (non-pyogenic thrombosis of intracranial venous system), I63.6 (cerebral infarction due to cerebral venous thrombosis, non-pyogenic), O22.5 (cerebral venous thrombosis in pregnancy) and O87.3 (cerebral venous thrombosis in the puerperium). Results: Sixty-five admissions were identified by at least one of the relevant ICD-10 codes. The overall positive predictive value (PPV) for confirmed ICVT from all of the admissions combined was 92.3% (60 out of 65) with the results for each code as follows: G08.X 91.5% (54 of 59), O22.5 100% (4 of 4), I67.6 100% (1 of 1), I63.6 100% (1 of 1) and O87.3 100% (1 of 1). There were 40 unique cases of ICVT over a 5-year period giving an annual incidence of ICVT of 5 per million. Conclusions: All codes gave a high PPV. Implications for practice: As demonstrated in previous studies, the incidence of ICVT may be higher than previously thought.

Download Full-text

Cerebral venous thrombosis and portal vein thrombosis: a retrospective cohort study of 537,913 COVID-19 cases

10.1101/2021.04.27.21256153 ◽

2021 ◽

Author(s):

Maxime Taquet ◽

Masud Husain ◽

John R Geddes ◽

Sierra Luciano ◽

Paul Harrison

Keyword(s):

Cohort Study ◽

Portal Vein ◽

Venous Thrombosis ◽

Portal Vein Thrombosis ◽

Retrospective Cohort Study ◽

Cerebral Venous Thrombosis ◽

Retrospective Cohort ◽

Matched Cohort ◽

Vein Thrombosis ◽

Icd 10

Objectives: To estimate the absolute risk of cerebral venous thrombosis (CVT) and portal vein thrombosis (PVT) in the two weeks following a diagnosis of COVID-19, and to assess the relative risks (RR) compared to influenza or the administration of an mRNA vaccine against COVID-19. Design: Retrospective cohort study based on an electronic health records network Setting: Linked records between primary and secondary care centres within 59 healthcare organisations, primarily in the USA Participants: All patients with a confirmed diagnosis of COVID-19 between January 20, 2020 and March 25, 2021 were included (N=537,913, mean [SD] age: 46.2 [21.4] years; 54.9% females). Cohorts (matched for age, sex, and race) of participants diagnosed with influenza (N=392,424) or receiving the BNT162b2 or mRNA-1273 vaccine (N=366,869) were used for comparison. Main outcome measures: Diagnosis of CVT (ICD-10 code I67.6) or PVT (ICD-10 code I81) within 2 weeks after a diagnosis of COVID-19. Results: The incidence of CVT after COVID-19 diagnosis was 42.8 per million people (95% CI 28.5-64.2) including 35.3 per million (95% CI 22.6-55.2) first diagnoses. This was significantly higher than the CVT incidence in a matched cohort of patients with influenza (RR=3.83, 95% CI 1.56-9.41, P<0.001) and people who received an mRNA vaccine (RR=6.67, 95% CI 1.98-22.43, P<0.001). The incidence of PVT after COVID-19 diagnosis was 392.3 per million people (95% CI 342.8-448.9) including 175.0 per million (95% CI 143.0-214.1) first diagnoses. This was significantly higher than the PVT incidence in a matched cohort of patients with influenza (RR=1.39, 95% CI 1.06-1.83, P=0.02) and people who received an mRNA vaccine (RR=7.40, 95% CI 4.87-11.24, P<0.001). Mortality after CVT and PVT was 17.4% and 19.9% respectively. Conclusions: The incidence of CVT and PVT is significantly increased after COVID-19. The data highlight the risk of serious thrombotic events in COVID-19 and can help contextualize the risks and benefits of vaccination in this regard.

Download Full-text

Cerebral venous thrombosis in traumatic brain injury: a cause of secondary insults and added mortality

Journal of Neurosurgery ◽

10.3171/2020.4.jns20511 ◽

2020 ◽

pp. 1-9

Author(s):

Dag Ferner Netteland ◽

Magnus Mejlænder-Evjensvold ◽

Nils O. Skaga ◽

Else Charlotte Sandset ◽

Mads Aarhus ◽

...

Keyword(s):

Traumatic Brain Injury ◽

Brain Injury ◽

Venous Thrombosis ◽

Subgroup Analysis ◽

Severity Score ◽

Cerebral Venous Thrombosis ◽

Control Group ◽

Mr Venography ◽

Adjusted Analysis ◽

Icd 10

OBJECTIVECerebral venous thrombosis (CVT) is increasingly recognized in traumatic brain injury (TBI), but its complications and effect on outcome remain undetermined. In this study, the authors characterize the complications and outcome effect of CVT in TBI patients.METHODSIn a retrospective, case-control study of patients included in the Oslo University Hospital trauma registry and radiology registry from 2008 to 2014, the authors identified TBI patients with CVT (cases) and without CVT (controls). The groups were matched regarding Abbreviated Injury Scale 1990, update 1998 (AIS’98) head region severity score 3–6. Cases were identified by AIS’98 or ICD-10 code for CVT and CT or MR venography findings confirmed to be positive for CVT, whereas controls had no AIS’98 or ICD-10 code for CVT and CT venography or MR venography findings confirmed to be negative for CVT. All images were reviewed by a neuroradiologist. Rates of complications due to CVT were recorded, and mortality was assessed both unadjusted and in a multivariable logistic regression analysis adjusting for initial Glasgow Coma Scale score, Rotterdam CT score, and Injury Severity Score. Complications and mortality were also assessed in prespecified subgroup analysis according to CVT location and degree of occlusion from CVT. Lastly, mortality was assessed in an exploratory subgroup analysis according to the presence of complications from CVT.RESULTSThe CVT group (73 patients) and control group (120 patients) were well matched regarding baseline characteristics. In the CVT group, 18% developed venous infarction, 11% developed intracerebral hemorrhage, and 19% developed edema, all representing complications secondary to CVT. Unadjusted 30-day mortality was 16% in the CVT group and 4% in the no-CVT group (p = 0.004); however, the difference was no longer significant in the adjusted analysis (OR 2.24, 95% CI 0.63–8.03; p = 0.215). Subgroup analysis by CVT location showed an association between CVT location and rate of complications and an unadjusted 30-day mortality of 50% for midline or bilateral CVT and 8% for unilateral CVT compared with 4% for no CVT (p < 0.001). The adjusted analysis showed a significantly higher mortality in the midline/bilateral CVT group than in the no-CVT group (OR 8.41, 95% CI 1.56–45.25; p = 0.032).CONCLUSIONSThere is a significant rate of complications from CVT in TBI patients, leading to secondary brain insults. The rate of complications is dependent on the anatomical location of the CVT, and midline and bilateral CVT is associated with an increased 30-day mortality in TBI patients.

Download Full-text